


This listing of claims will replace all prior versions, and listings, of claims in the application:


LISTING OF CLAIMS:

1. **(Currently Amended)** A method for improving perception, concentration, cognitive processes, learning and/or memory comprising administering to a human or animal an effective amount of a selective PDE9A inhibitor, where the selective PDE9A inhibitor is a compound of one of the following formula (I) or (II):



(I)

or



(II)


or a salt or solvate or solvate of a salt thereof.

2. **(Currently Amended)** The method as claimed in claim 1 for the treatment of impairments of perception, concentration, cognitive processes, learning and/or memory in a human or animal having such an impairment.
3. **(Previously presented)** The method as claimed in claim 2, where the impairment is a consequence of a disorder selected from the group consisting of dementia, stroke, craniocerebral trauma, Alzheimer's disease, Parkinson's disease, depression, or dementia with degeneration of the frontal lobes.

4. – 9. (Canceled)


- 10. (Previously presented)** The method of claim 1, wherein the selective PDE9A inhibitor is administered parenterally in an amount of 0.001 to 30 mg/kg of the human or animal body weight.
- 11. (Previously presented)** The method of claim 1, wherein the selective PDE9A inhibitor is administered parenterally in an amount of 0.01 to 10 mg/kg of the human or animal body weight.
- 12. (Previously presented)** The method of claim 1, wherein the selective PDE9A inhibitor is administered orally in an amount of 0.01 to 100 mg/kg of the human or animal body weight.
- 13. (Previously presented)** The method of claim 1, wherein the selective PDE9A inhibitor is administered orally in an amount of 0.1 to 30 mg/kg of the human or animal body weight.
- 14. (Currently Amended)** The method of claim 1, wherein the selective PDE9A inhibitor is a compound of formula (I) or ~~a salt or solvate or solvate of a salt thereof~~.
- 15. (Currently Amended)** The method of claim 2, wherein the selective PDE9A inhibitor is a compound of formula (I) or ~~a salt or solvate or solvate of a salt thereof~~.
- 16. (Currently Amended)** The method of claim 3, wherein the selective PDE9A inhibitor is a compound of formula (I) or ~~a salt or solvate or solvate of a salt thereof~~.
- 17. (Currently Amended)** The method of claim 1, wherein the selective PDE9A inhibitor is a compound of formula (II) or ~~a salt or solvate or solvate of a salt thereof~~.

18. **(Currently Amended)** The method of claim 2, wherein the selective PDE9A inhibitor is a compound of formula (II) or ~~a salt or solvate or solvate of~~ a salt thereof.
19. **(Currently Amended)** The method of claim 3, wherein the selective PDE9A inhibitor is a compound of formula (II) or ~~a salt or solvate or solvate of~~ a salt thereof.
20. **(Currently Amended)** A compound of one of the following formulae:



(I)


or



(II)


or ~~a salt or solvate or solvate of~~ a salt thereof.

21. **(Currently Amended)** A compound of claim 20, which is a compound of formula (I) or ~~a salt or solvate or solvate of~~ a salt thereof.
22. **(Currently Amended)** A compound of claim 20, which is a compound of formula (II) or ~~a salt or solvate or solvate of~~ a salt thereof.
23. **(New)** A method for producing a medicament useful for improving perception, concentration, cognitive processes, learning and/or memory comprising providing a compound of one of the following formula (I) or (II):



(I)


or



(II)


or a salt thereof, in a form useful for improving perception, concentration, cognitive processes, learning and/or memory in a human or animal.

24. (New) A pharmaceutical composition comprising a compound of one of the following formula (I) or (II):



(I)

or



(II)

or a salt thereof, as the active moiety.